Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience

被引：0
|
作者：
Omarini, C. [1 ]
Medici, G. [1 ]
Guaitoli, G. [1 ]
Iattoni, E. [1 ]
Moscetti, L. [1 ]
Balduzzi, S. [1 ]
Cascinu, S. [1 ]
Piacentini, F. [1 ]
机构：
[1] Univ Modena Policlin, Modena, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw337.55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F55
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [32] T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice
    Michel, Laura L.
    Bermejo, Justo Lorenzo
    Gondos, Adam
    Marme, Frederik
    Schneeweiss, Andreas
    ANTICANCER RESEARCH, 2015, 35 (09) : 5085 - 5090
  • [33] Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer
    Geraud, Arthur
    Xu, Hao Ping
    Beuzeboc, Philippe
    Kirova, Youlia M.
    JOURNAL OF NEURO-ONCOLOGY, 2017, 131 (01) : 69 - 72
  • [34] mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
    Casadevall, David
    Hernandez-Prat, Anna
    Garcia-Alonso, Sara
    Arpi-Llucia, Oriol
    Menendez, Silvia
    Qin, Mengjuan
    Guardia, Cristina
    Morancho, Beatriz
    Sanchez-Martin, Francisco Javier
    Zazo, Sandra
    Gavilan, Elena
    Sabbaghi, Mohammad A.
    Eroles, Pilar
    Cejalvo, Juan Miguel
    Lluch, Ana
    Rojo, Federico
    Pandiella, Atanasio
    Rovia, Ana
    Anabell, Joan
    MOLECULAR CANCER RESEARCH, 2022, 20 (07) : 1108 - 1121
  • [35] Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer
    Arthur Geraud
    Hao Ping Xu
    Philippe Beuzeboc
    Youlia M. Kirova
    Journal of Neuro-Oncology, 2017, 131 : 69 - 72
  • [36] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [37] T-DM1 for residual, invasive, HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2019, 20 (01): : E13 - E13
  • [38] Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
    Tian, Hao
    Qu, Man
    Zhang, Guozhi
    Yuan, Long
    Shi, Qiyun
    Wang, Yinhuan
    Yang, Ying
    Zhang, Yi
    Qi, Xiaowei
    ONCOLOGIST, 2023, 28 (07): : E534 - E541
  • [39] Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)
    Krop, I. E.
    Burris, H. A.
    Rugo, H.
    O'Shaughnessy, J.
    Vogel, C. L.
    Amler, L.
    Strauss, A.
    Wong, E. K.
    Klencke, B.
    Pippen, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+metastatic breast cancer previously treated with T-DM1
    Hurvitz, Sara
    Kalinsky, Kevin
    Ganju, Vinod
    Ali, Kashif
    Agrawal, Laila
    Gradishar, William
    Sledge, George
    Thummala, Anu
    Chan, Arlene
    Frentzas, Sophia
    Sohn, Joo Hyuk
    Park, Kyong-Hwa
    Park, Keon Uk
    Shannon, Catherine
    Drago, Joshua
    Tolaney, Sara
    Rugo, Hope
    Press, Michael F.
    Alika, Alex
    Xu, Dong
    Lu, Janice
    Tripathy, Debu
    CANCER RESEARCH, 2023, 83 (05)
12345